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http://www.lipidworld.com/content/13/1/125RESEARCH Open AccessEfficacy of yogurt drink with added plant stanol
esters (Benecol®, Colanta) in reducing total and
LDL cholesterol in subjects with moderate
hypercholesterolemia: a randomized placebo-
controlled crossover trial NCT01461798
Elsa M Vásquez-Trespalacios* and Johanna Romero-PalacioAbstract
Background: Cardiovascular diseases have become the leading cause of death from chronic diseases in the world.
Main risk factors include hypercholesterolemia, which is caused in most cases by a high saturated fat diet. Plant
stanol esters partly block cholesterol absorption in the digestive tract and thereby reduce total cholesterol and
low-density lipoprotein (LDL) cholesterol serum levels. Based on epidemiological data, a 10 percent reduction of
LDL cholesterol leads to a 20 percent decrease in the coronary heart disease risk throughout life. The aim of this
study was to evaluate the efficacy of yogurt drink with added plant stanol esters (Benecol® yogurt drink) in higher
doses than the typically used (2g/d stanols), in lowering blood lipids in moderately hypercholesterolemic subjects.
Methods: A randomized double-blind crossover, placebo-controlled study in moderately hypercholesterolemic
subjects (n = 40) aged between 20 and 50 years old.
Results: Yogurt drink with added plant stanols (4 g) as esters (Benecol®, Colanta) consumption compared to regular
yogurt drink caused a statistically significant decrease in total cholesterol and low density lipoprotein cholesterol
by 7.2% and 10.3%. During the two periods and compared to controls, high-density lipoprotein cholesterol and
triglycerides were not significantly different.
Conclusions: Yogurt drink with an active ingredient in Benecol®, plant stanol esters, reduced total cholesterol and
LDL cholesterol in moderately hypercholesterolemic subjects.
Trial registration: NCT01461798
Keywords: Hypercholesterolemia, Low-density lipoproteins, Cardiovascular diseases, Plant stanol ester, CrossoverBackground
Phytosterols and their saturated form phytostanols, are
naturally found in fruits, vegetables, nuts, seeds, legumes,
vegetable oils, and from other sources [1-4]. Structurally,
they are similar to cholesterol, but their absorption rate is
much lower. Foods with added plant stanol esters, which
could be cholesterol-lowering functional foods, provide
the consumer an opportunity for cardiovascular disease
prevention [5].* Correspondence: elsamariavtres@gmail.com
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and plant stanols lies in the reduced intestinal absorp-
tion due to a replacement of cholesterol in intestinal
micelles [6]. The structural similarities to cholesterol are
responsible for both hypocholesterolemic effects and
also lowered absorption at the intestinal level [7,8]. Tests
indicate an intestinal effect that decreases cholesterol ab-
sorption [9-11], which gains an important place in strat-
egies to reduce cardiovascular risk [12].
Several clinical studies show that plant stanol esters are
effective for lowering plasma total and LDL-cholesterol
(LDL-C) levels [13-15] and this reduction occurscio; licensee BioMed Central Ltd. This is an Open Access article distributed
tribution License (http://creativecommons.org/licenses/by/4.0), which permits
n in any medium, provided the original work is properly credited. The Creative
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Table 1 Subject characteristics at baseline
Parameter All subjects
Age (years) Mean 37.9
SD 8.5
Range 25-50
Weight (kg) Mean 65.6
SD 10.3
Range 48-91
Height (m) Mean 1.62
SD 0.08
Range 1.45-1.80
BMI (kg/m2) Mean 25.0
SD 3.4
Range 18.5-33.3
Sex Female 30 (75.0%)
Male 10 (25.0%)
Body mass index categories 18.5-24.9 20 (50.0%)
25.0-29.9 17 (42.5%)
30.0-34.9 3 (7.5%)
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added dietary plant stanol esters [16]. With a regular con-
sumption, the effect remains constant at least up to a year
[13]. A meta-analysis of both plant stanol and plant sterol
ester studies yielded on average an 8.8% reduction in
LDL-cholesterol for a mean daily dose of 2.15 g phy-
tosterols [17]. Such a reduction in LDL-C is beneficial
for cardiovascular health. Based on epidemiological
data, a 10 percent reduction of LDL cholesterol leads
to a 20 percent decrease in the coronary heart disease
risk throughout life [18].
A review of clinical evidence supports the notion that
higher doses than currently recommended of plant sta-
nol esters could have a dose-effect relationship between
consumption and reduced serum LDL cholesterol con-
centrations [19]. A meta-analysis of 113 publications
suggests that an ingestion of more than 2 g/day of plant
stanols is associated with an additional LDL-C reduction
compared to the lower doses [20]. The recent European
Food Safety Authority Panel in Dietetic Products, Nutri-
tion, and Allergies concluded that plant stanol esters at
a daily intake of three grams (range 2.7 g to 3.3 g) low-
ered LDL-cholesterol by 11.4 percent [21].
Here, we evaluated the efficacy of a yogurt drink with
added plant stanols as esters (in Benecol®, Colanta) in
higher than the typically recommended dose in reducing
total and LDL cholesterol in Colombian subjects with
moderate hypercholesterolemia. This is the first study
that investigates the efficacy of four grams of plant sta-
nols as ester incorporated in a yogurt drink administered
in two portions, daily.
Results
Clinical characteristics of subjects
We evaluated forty subjects, average age of 37.9 years, of
whom the majority were women (n = 30, 75%). The average
weight was 65.6 kg (62.9 kg for women and 73.7 kg for
men) and is shown in Table 1. No differences in baseline
variables according to the treatment sequence were found.
All subjects in the study were compliant to the in-
tervention, with a consumption percentage reaching 80
percent, which was verified by counting the unopened
and empty containers before each new delivery. During
the entire follow-up period, none of the subjects suffered
serious adverse events or other qualifying events. Four
percent of the volunteers indicated that yogurt drink
consumption improved their intestinal transit.
All subjects underwent tests for liver, kidney function,
and blood count to check health conditions. None of the
subjects suffered from any disease or disorder than mod-
erate hypercholesterolemia. Laboratory tests confirmed
that there was no abnormality. There was no change in
these laboratory analyses regarding the order of the in-
tervention, Table 2.Differences in measurements of the above mentioned
tests, did not exceed the limits established in the labora-
tory reference values. The limits of biological variability
according to Westgard states for ALT changes an inter-
individual variation coefficient of 18 percent, for the AST
of 11.9 percent, for serum creatinine 6 percent, alkaline
phosphatase 6.4 percent, hemoglobin and hematocrit 2.8
percent, lymphocytes 10.4 percent, and platelet count of
9.1 percent. These values were not overcome by measur-
ing the changes in subjects [22].
Effect of treatments on blood lipids
Following a four-week consumption of Benecol® yogurt
drink, total cholesterol was reduced by 15.6 mg/dl and
proportionally by 7.2 percent compared to placebo drink
(p = 0.001, Tables 3 and 4) The reduction of LDL cholesterol,
when measured directly or calculated by the Friedwald
equation was higher. LDL cholesterol was higher during the
intervention period mounting to 10.3 percent and 12.2 per-
cent, respectively (p < 0.001, Table 3, Figure 1).
No statistically significant change for either HDL chol-
esterol (p = 0.735) or triglycerides (TG) (p = 0.999) were
detected (Table 4, Figure 1). No period or carry-over ef-
fects were detected for any of the lipid outcome vari-
ables (all NS).
A significant difference existed between men and wo-
men’s baseline HDL cholesterol, non-HDL cholesterol,
and in TG (data not shown). In a cross-over study, these
differences are not important because the analysis is based
on within-subject comparison, not on the between-subjects
comparisons. Between BMI groups, the differences were








Serum (S) ALAT IU/l Median IQR
20.0 21.0
16.0-32.3 16.3-30.5
S ASAT IU/l Median IQR
23.0 23.0
19.3-26.8 19.3-25.0
S Crea mg/dl Median IQR
0.90 0.88
0.81-1.00 0.77-1.01
S AFOS U/l Median IQR
64.0 66.0
50.3-82.3 54.3-79.8
Blood (B)Hb g/dl Median IQR
14.1 14.3
13.5-15.4 13.6-15.3
B Hkr% Median IQR
40.8 41.4
39.5-44.0 39.7-44.1
B Lymp% Median IQR
37.1 40.5
32.5-42.1 34.9-45.6
B Tromb mm3 Median IQR
279.5 284.5
223.0-318.5 228.3-331.5
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overweight (BMI≥ 25 kg/m2) was observed in 14 women
(46.7%) and in six men (60.0%) without significant difference
(p = 0.465, Chi-squared test). All interactions between gen-
der/BMI were nos significant (p > 0.20 in all analyses).
In the sub-group evaluation of the impact of gender
and BMI status (overweight vs. normal weight) for total-Table 3 Serum lipids (mg/dl) at the end of 4 weeks Benecol®
Benecol P
Mean (95% CI) M
Total cholesterol (mg/dL) 205.5 (197.9 – 213.2) 2
HDL cholesterol (mg/dL) 49.6 (45.8 - 53,4) 4
LDL cholesterol measured (mg/dL) 108.7 (102.3 – 115.0) 1
LDL cholesterol calculated (mg/dL) 125.8 (117.9 – 133.7) 1
Non-HDL cholesterol (mg/dL) 155.9 (147.3 - 164.5) 1
TG3 (mg/dL) 176.4 (137.2 – 215.7) 1
3The distribution of TG was skew to the right.
After logarithmic transformation, the geometric means were 146.2 in Benecol® andand LDL-cholesterol-lowering by plant stanols, subjects
with a BMI of less than 25 kg/m2 total cholesterol reduc-
tion during Benecol® treatment (vs. placebo) was somewhat
larger (18.5 mg/dl, 8.6%) compared to those whose BMI
was greater than or equal to 25 (12.6 mg/dl, 5.8%). LDL
reduction showed the opposite trend (11.3 mg/dl, 9.6%)
and (12.8 mg/dl, 11.0%), in BMI of less than 25 and BMI
greater than or equal to 25, respectively. In men, the chol-
esterol reduction during Benecol® treatment (vs. placebo)
was (16.9 mg/dl, 7.2%) and in women (15.4 mg/dl, 7.4%).
LDL-cholesterol reduction was 14.2 mg/dl (10.8%) and
11.8 mg/dl (10.7%), in men and women, respectively.
Discussion
We showed that after four weeks of consuming Benecol®
yogurt drinks with four grams of added plant stanols, a
decrease in total cholesterol by 7.2 percent occurred and
in LDL-cholesterol by 10.3 percent.
These results are in line to those reported previ-
ously, when determining that the consumption of plant
sterols decreases serum total cholesterol levels and LDL-
cholesterol values by 7 to 10 percent [23-25]. The mech-
anism by which this effect is achieved is related to reduced
cholesterol absorption of both dietary and biliary origin
[26,27]. Studies in rat models confirm that stanols are
absorbed poorly [28]. Evidence suggests that intake of
the recommended (2 g/day) or higher dose of plant sta-
nols produces neither serious adverse effects nor health
risks of concern, but provides potential benefits for
cardiovascular health through reduced serum choles-
terol levels [26].
The higher dose used in this study did not provide an
enhanced effect. The time of intake was reported to be
ideal for inducing the physiological changes to allow
plant stanols to compete over cholesterol absorption
[29]. However, the subjects might not have consumed
the yogurt drink immediately after a meal and thus the
liquid nature of the food product might have influenced
the cholesterol-lowering efficacy. This may be the case
as in the previous studies using yogurt drinks as the
cholesterol-lowering efficacy is achieved by smaller dosesand at the end of placebo treatment
lacebo Benecol® vs. placebo p
ean (95% CI) Mean (95% CI)
21.1 (212.8 – 229.4) −15,6 (-24.2 to -6.9) 0.001
9.5 (45.1 – 53.9) 0.1 (-4.0 to 4.3) 0.95
20.7 (113.5 – 127.8) −12.0 (-16.5 to -7.5) <0.001
42.2 (134.0 – 150.4) −16.4 (-23.4 to -9.3) <0.001
71.6 (162.5 – 180.7) −15.7 (-23.0 to -8.3) <0.001
68.8 (138.7 – 198.9) 7.6 (-23.9 to 39.1) 0.63
149.4 in placebo (p = 0.76).
Table 4 Percentage changes in serum lipids from first-period baseline to the end of 4 weeks Benecol and to the end of
placebo treatment and differences in responses between treatments
Benecol Placebo Benecol® vs. placebo p1
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Total cholesterol −7.7 (-10.5 to -4.9) −0,5 (-4.0 to 3.1) −7.2 (-11.1 to -3.3) 0.001
HDL cholesterol −1,1 (-4.8 to 2.6) −0,1 (-6.9 to 6.8) −1.1 (-7.3 to 5.2) 0.735
LDL cholesterol measured −10,4 (-14.0 to -6.9) −0,1 (-5.1 to 4.9) −10.3 (-14.3 to -6.4) <0.001
LDL cholesterol calculated −11,5 (-16.6 to -6.4) 0,7 (-5.6 to 7.0) −12.2 (-17.3 to -7.2) <0.001
Non-HDL cholesterol −9,3 (-12.9 to -5.8) 0,2 (-4.5 to 5.0) −9.6 (-14.1 to -5.0) <0.001
TG3 18,2 (1.6 to 34.8) 18,2 (3.2 to 33.3) 0.0 (-18.9 to 18.9) 0.999
1Test.
After logarithmic transformation the geometric means were 146.2 in Benecol® and 149.4 in placebo (p = 0.76).
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co-workers, a 10.3 percent reduction in LDL-cholesterol
and in the study by Krienginyos, a 13.5 percent reduction
was achieved by two grams of plant stanols in a yogurt
drink [30,31]. Interestingly, Seppo et al. administered the
yogurt drink under supervision in a café and an 11 percent
reduction in LDL-cholesterol was detected, while only a
3.2 percent reduction was achieved when the consump-
tion of the test product took place unsupervised [25].
LDL-cholesterol-lowering obtained with plant stanol
ester consumption is important because it exceeds the
effect that can be reached by doubling the dose of any
kind of statin alone could reach by approximately six
percent. Combining statins with plant stanols in subjects
requiring further reduction of cholesterol may be effect-
ive and safer for the patient rather than doubling the
dose of statins [27].
Sterols or stanols have no effect on cholesterol bound
to high-density lipoprotein (HDL) and triglycerides, a re-
sult that we also observed in this study as no significant
changes were obtained in HDL cholesterol and triglycer-







Figure 1 Difference between plant stanol ester and placebo
treatments for serum lipids (% change from first-period baseline).In hypertriglyceridemic subjects, consumption of plant
stanols decreases serum triacylglycerols (>2.3 mmol/L;
p = 0.009) [33]. In this study, changes in triglycerides
were not significant in subjects without elevated trigly-
ceride levels.
Plasma phytosterols, in addition to lowering lipid
levels, are markers of a healthy diet and a lower cardio-
metabolic risk [34].
So far, the only contraindication in the consumption
of these compounds is the presence of sitosterolemia; an
uncommon metabolic defect as is, characterized by an
intestinal hyperabsorption of all sterols consumed in or-
dinary food, which is associated with premature athero-
sclerosis [35].
According to epidemiological data, a 10 percent reduc-
tion of LDL cholesterol leads to a 20 percent decrease in
the coronary heart disease risk throughout life [18].
Conclusions
Yogurt drink with added plant stanol esters reduced to-




Volunteers were recruited and were people working or
living in the neighborhood next to the laboratory where
tests were performed. Before inclusion, blood samples
were drawn to choose subjects with mild hypercholes-
terolemia (serum total cholesterol of 5.2 to 7.5 mmol/l
(205-290 mg/dl)). Subjects with lipid-lowering medica-
tion or other drugs that significantly affect lipid values,
diabetes type I or II, severe obesity (BMI greater than
35 kg/m2), fasting serum triglycerides > 4.0 mmol/l, liver,
or kidney disorder according to medical history, history
of coronary revascularization, percutaneous transluminal
coronary angioplasty within six months prior to screening,
history of temporary ischemic attack or stroke within
six months prior to screening, history of cancer or other
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more than 15 dosages of alcohol/week, pregnant or lactat-
ing, Benecol® consumption in their diet, or other plant
stanol or sterol enriched products 30 days before visit
2 (Week 1), severe lactose intolerance, milk allergy, or
any other form of intolerance to the ingredients of the
test products, celiac disease were excluded.
This study was approved by the Institutional Ethics
Committee at Universidad CES, Medellín, Colombia and
all subjects gave informed consent.
Study design
This study used a double blind, placebo-controlled and
randomized crossover study with two treatment periods
lasting four weeks each, separated by a one-week wash
out period (Figure 2). 60 moderately hypercholesterolemic
volunteers were invited to participate and 40 of them met
the inclusion criteria. The subjects were randomized and
one group received the Benecol® yogurt drink and the
other group consumed placebo yogurt during four weeks
(20 subjects per group). After a one-week wash-out per-
iod, the subjects who started with Benecol yogurt drink
received the placebo yogurt drink and the subjects starting
with placebo drink received Benecol yogurt drink for the
next four weeks. Randomization of subjects was per-
formed in (EPIDAT) version 3.1. Randomization, inclu-
sion, and allocation of subjects to each group were made
by the principal investigators.
The producers of the test product (COLANTA,
Medellín, Colombia) were the only who knew the al-
located intervention and both researchers and study
participants were blind of this assignment, which was
revealed once the study was completed. During the
study, subjects were asked to keep their habitual diet
and physical activity pattern unchanged. There wasFigure 2 Intervention scheme.no other dietary intervention during the study except
the consumption of the yogurt drink.
Intervention
Blood sample was drawn at week zero for the assess-
ment of the lipid profile and these results found that 40
subjects met the inclusion criteria. At week 1, a new
blood sample was taken and this time subjects underwent
tests to check liver and kidney function to meet the basic
health conditions, after these results, subjects were al-
located to consume placebo yogurt drink or Benecol®
yogurt drink (200 ml of yogurt a day as part of main meals,
corresponding to 4 g of plant stanols as esters, daily) during
four weeks. At the beginning of week 5, a new sample of
blood from subjects was taken for determining lipid profile
including total cholesterol LDL-cholesterol, triglycerides,
and HDL cholesterol, subjects had a week off (washout
period), and at week 6, groups were changed, (those con-
suming placebo yogurt were changed to Benecol yogurt
drink and vice versa). At the end of week ten, a blood
sample was drawn to verify that subject’s baseline liver
and renal function were preserved and to measure
changes in lipid levels (Figure 2).
Yogurt drinks
The two study drinkable yogurts were produced by the
dairy cooperative COLANTA (Medellin, Colombia)
under controlled conditions, established in the produc-
tion area, packed in a white package and labeled at the
top with an expiration date and indicative of sample 1
and sample 2 to maintain the blinding setup.
Sample 1: Placebo Yogurt drink, 2 pots/day.
Sample 2: Benecol® Yogurt drink with 2 g of plant sta-
nols as esters per 100 ml, 2 pots/day.
Nutrient composition per 100 ml of the yogurt drink:





Plant stanols 2.0 g
Supply of yogurt drinks was conducted between July
to September 2012, subjects were given detailed instruc-
tions on how to use the test products. Yogurt drinks
were produced once a week and delivered to the sub-
jects. The study participants were advised to consume
the yogurt drink with meals.
Compliance
Compliance was assessed by interviewing subjects and
by recording yogurt drink consumption. The subjects
returned both unopened and empty consumed packages
to the principal investigator which allowed determining
the percentage of servings of yogurt drinks consumed by
each subject at the scheduled time. Non-compliance to
the study protocol was defined as less than 80% of con-
sumption of the test yogurt drink.
Safety
Some variables of interest were assessed in order to ensure
the safety of volunteers; measurement of alanine amino-
transferase (ALT), aspartate aminotransferase (AST), cre-
atinine, alkaline phosphatase, hemoglobin, hematocrit,
lymphocytes, platelet count was performed at first week to
volunteers entry to the study; i.e., before starting the inter-
vention and at the end of week ten.
Analytical methods
Fasting blood samples were taken by venipuncture at
baseline, week 5 and week 10. All venipuncture were ge-
nerally carried out by the same person, at the same loca-
tion. Subjects were asked to fast for at least eight hours
before blood samples were taken. ALT, AST, FA, creatin-
ine, LDL cholesterol and HDL cholesterol were assessed
through an enzymatic technique (Biosystem®) United
States. LDL-C was also calculated by Friedewald’s equa-
tion. Total cholesterol and triglycerides were assessed
through a colorimetric technique (Biosystem®).
Statistical analysis
Sample size calculations were based on the following as-
sumptions. It was assumed that the effect of Benecol®
(vs. placebo) on the change in LDL cholesterol is be-
tween -8% and -12% and SD of within-subjects changes
is 15% during both interventions. A sample size of 38
subjects will have 90% power to detect the 8% difference
between Benecol® and placebo treatments statistically
significant with a 0.05 two-sided significance level. The
differences of 10% and 12% between Benecol® and placebowould require smaller sample sizes, 25 and 17 subjects,
respectively.
Baseline characteristics for subjects in the two treat-
ment sequences were compared using Chi-squared test
for categorical variables, Mann-Whitney U test for labo-
ratory safety variables and t-test for independent samples
for other continuous variables.
Serum total cholesterol and LDL-cholesterol (both dir-
ect measured and calculated by Friedewald equation) were
the primary outcome variables. Serum HDL-cholesterol,
non-HDL cholesterol, and triglycerides (TG) were the sec-
ondary outcome variables. The primary and secondary
variables were evaluated after the run-in period (before
the first treatment period) referred to as the “first-period
baseline” and at the end of each treatment period, referred
to as “end of treatment”.
For all serum lipids both absolute values (mg/dl) at the
end of treatments and percentage change (% change)
from first-period baseline were analyzed. Repeated mea-
sures analysis of variance (ANOVA) for cross-over de-
signs was used to test the effects of treatment, period,
and carry-over. Although there were no significant
period or carry-over effects for lipid variables expressed
as absolute value or percentage change, the order of
treatments was included in all models. The results are
given as means with 95% confidence intervals. The dis-
tribution of serum triglyceride (mg/dl) was skew to the
right and the analysis was repeated using the logarith-
mically transformed values. Statistical analyses were per-
formed according to the intention to treat. All tests were
two-sided and a p < 0.05 was considered to indicate a
significant difference. Statistical analyses were performed
using IBM SPSS Statistics (version 22.0, Armonk, NY:
IBM Corp.).Abbreviations
HDL: High-density lipoprotein; LDL: Low-density lipoprotein; ALT: Alanine
transaminase; AST: Aspartate transaminase; BMI: Body mass index;
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